JSJatinder Saini

Jatinder Saini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jatinder Saini has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Tony Wong

    Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St., Seattle, WA 98133, United States; Departments of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA 98195, United States

    5 shared publications
  • Charles Bloch

    Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St., Seattle, WA 98133, United States; Departments of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA 98195, United States

    4 shared publications
  • Dominic Maes

    Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St., Seattle, WA 98133, United States; Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2500, Australia

    3 shared publications
  • Alexander Egan

    Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St., Seattle, WA 98133, United States

    2 shared publications
  • Martin Janson

    RaySearch Laboratories, Sveavägen 44, 111 34 Stockholm, Sweden

    2 shared publications
  • Rajesh Regmi

    Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St., Seattle, WA 98133, United States

    2 shared publications

Latest Publications

  • Open Access

    NRG Oncology Liver Proton SBRT and Hypofractionated Radiation Therapy: Current Treatment Technical Assessment and Practice Patterns

    by Minglei Kang, Paige A. Taylor, Jiajian Shen, Jun Zhou, Jatinder Saini, Theodore S. Hong, Kristin Higgins, Wei Liu, Ying Xiao, Charles B. Simone, et al.

    Background/Objectives: Proton therapy delivers highly conformal doses to the target area without producing an exit dose, minimizing cumulative doses to healthy liver tissue. This study aims to evaluate current practices, challenges, and variations in the implementation of proton stereotactic body radiation therapy (SBRT) and hypofractionated therapy for liver malignancies, with the goal of providing a technical assessment to promote broader adoption and support future clinical trials. Methods and Materials: An extensive survey was conducted by NRG Oncology across North American proton treatment centers to assess the current practices of proton liver SBRT and hypofractionated therapy. The survey focused on key aspects, including patient selection, prescription and normal tissue constraints, simulation and motion management, treatment planning, quality assurance (QA), treatment delivery, and the use of image-guided radiation therapy (IGRT). Results: This survey captures the current practice patterns and status of proton SBRT and hypofractionated therapy in liver cancer treatment. Proton therapy is increasingly preferred for treating inoperable liver malignancies due to its ability to minimize healthy tissue exposure. However, the precision required for proton therapy presents challenges, particularly in managing uncertainties and target motion during high-dose fractions and short treatment courses. Survey findings revealed significant variability in clinical practices across centers, highlighting differences in motion management, dose fractionation schedules, and QA protocols. Conclusion: Proton SBRT and hypofractionated therapy offer significant potential for treating liver malignancies. A comprehensive approach involving precise patient selection, treatment planning, and QA is essential for ensuring safety and effectiveness. This survey provides valuable insights into current practices and challenges, offering a foundation for technical recommendations to optimize the use of proton therapy and guide future clinical trials.


  • Validation and practical implementation of seated position radiotherapy in a commercial TPS for proton therapy

    by Dominic Maes, Martin Janson, Rajesh Regmi, Alexander Egan, Anatoly Rosenfeld, Charles Bloch, Tony Wong, Jatinder Saini


  • Open Access

    Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness

    by Yolanda D. Tseng, Shadonna M. Maes, Gregory Kicska, Patricia Sponsellor, Erik Traneus, Tony Wong, Robert D. Stewart, Jatinder Saini

    Background: Existing pencil beam analytical (PBA) algorithms for proton therapy treatment planning are not ideal for sites with heterogeneous tissue density and do not account for the spatial variations in proton relative biological effectiveness (vRBE). Using a commercially available Monte Carlo (MC) treatment planning system, we compared various dosimetric endpoints between proton PBA, proton MC, and photon treatment plans among patients with mediastinal lymphoma. Methods: Eight mediastinal lymphoma patients with both free breathing (FB) and deep inspiration breath hold (DIBH) CT simulation scans were analyzed. The original PBA plans were re-calculated with MC. New proton plans that used MC for both optimization and dose calculation with equivalent CTV/ITV coverage were also created. A vRBE model, which uses a published model for DNA double strand break (DSB) induction, was applied on MC plans to study the potential impact of vRBE on cardiac doses. Comparative photon plans were generated on the DIBH scan. Results: Re-calculation of FB PBA plans with MC demonstrated significant under coverage of the ITV V99 and V95. Target coverage was recovered by re-optimizing the PT plan with MC with minimal change to OAR doses. Compared to photons with DIBH, MC-optimized FB and DIBH proton plans had significantly lower dose to the mean lung, lung V5, breast tissue, and spinal cord for similar target coverage. Even with application of vRBE in the proton plans, the putative increase in RBE at the end of range did not decrease the dosimetric advantages of proton therapy in cardiac substructures. Conclusions: MC should be used for PT treatment planning of mediastinal lymphoma to ensure adequate coverage of target volumes. Our preliminary data suggests that MC-optimized PT plans have better sparing of the lung and breast tissue compared to photons. Also, the potential for end of range RBE effects are unlikely to be large enough to offset the dosimetric advantages of proton therapy in cardiac substructures for mediastinal targets, although these dosimetric findings require validation with late toxicity data.


  • Advanced Proton Beam Dosimetry Part I: review and performance evaluation of dose calculation algorithms

    by Jatinder Saini, Erik Traneus, Dominic Maes, Rajesh Regmi, Stephen R. Bowen, Charles Bloch, Tony Wong

    The accuracy of dose calculation is vital to the quality of care for patients undergoing proton beam therapy (PBT). Currently, the dose calculation algorithms available in commercial treatment planning systems (TPS) in PBT are classified into two classes: pencil beam (PB) and Monte-Carlo (MC) algorithms. PB algorithms are still regarded as the standard of practice in PBT, but they are analytical approximations whereas MC algorithms use random sampling of interaction cross-sections that represent the underlying physics to simulate individual particles trajectories. This article provides a brief review of PB and MC dose calculation algorithms employed in commercial treatment planning systems and their performance comparison in phantoms through simulations and measurements. Deficiencies of PB algorithms are first highlighted by a simplified simulation demonstrating the transport of a single sub-spot of proton beam that is incident at an oblique angle in a water phantom. Next, more typical cases of clinical beams in water phantom are presented and compared to measurements. The inability of PB to correctly predict the range and subsequently distal fall-off is emphasized. Through the presented examples, it is shown how dose errors as high as 30% can result with use of a PB algorithm. These dose errors can be minimized to clinically acceptable levels of less than 5%, if MC algorithm is employed in TPS. As a final illustration, comparison between PB and MC algorithm is made for a clinical beam that is use to deliver uniform dose to a target in a lung section of an anthropomorphic phantom. It is shown that MC algorithm is able to correctly predict the dose at all depths and matched with measurements. For PB algorithm, there is an increasing mismatch with the measured doses with increasing tissue heterogeneity. The findings of this article provide a foundation for the second article of this series to compare MC vs. PB based lung cancer treatment planning.


  • Dosimetric evaluation of a commercial proton spot scanning Monte-Carlo dose algorithm: comparisons against measurements and simulations

    by Jatinder Saini, Dominic Maes, Alexander Egan, Stephen R Bowen, Sara St James, Martin Janson, Tony Wong, Charles Bloch

    RaySearch Americas Inc. (NY) has introduced a commercial Monte Carlo dose algorithm (RS-MC) for routine clinical use in proton spot scanning. In this report, we provide a validation of this algorithm against phantom measurements and simulations in the GATE software package. We also compared the performance of the RayStation analytical algorithm (RS-PBA) against the RS-MC algorithm. A beam model (G-MC) for a spot scanning gantry at our proton center was implemented in the GATE software package. The model was validated against measurements in a water phantom and was used for benchmarking the RS-MC. Validation of the RS-MC was performed in a water phantom by measuring depth doses and profiles for three spread-out Bragg peak (SOBP) beams with normal incidence, an SOBP with oblique incidence, and an SOBP with a range shifter and large air gap. The RS-MC was also validated against measurements and simulations in heterogeneous phantoms created by placing lung or bone slabs in a water phantom. Lateral dose profiles near the distal end of the beam were measured with a microDiamond detector and compared to the G-MC simulations, RS-MC and RS-PBA. Finally, the RS-MC and RS-PBA were validated against measured dose distributions in an Alderson–Rando (AR) phantom. Measurements were made using Gafchromic film in the AR phantom and compared to doses using the RS-PBA and RS-MC algorithms. For SOBP depth doses in a water phantom, all three algorithms matched the measurements to within ±3% at all points and a range within 1 mm. The RS-PBA algorithm showed up to a 10% difference in dose at the entrance for the beam with a range shifter and >30 cm air gap, while the RS-MC and G-MC were always within 3% of the measurement. For an oblique beam incident at 45°, the RS-PBA algorithm showed up to 6% local dose differences and broadening of distal fall-off by 5 mm. Both the RS-MC and G-MC accurately predicted the depth dose to within ±3% and distal fall-off to within 2 mm. In an anthropomorphic phantom, the gamma index (dose tolerance = 3%, distance-to-agreement = 3 mm) was greater than 90% for six out of seven planes using the RS-MC, and three out seven for the RS-PBA. The RS-MC algorithm demonstrated improved dosimetric accuracy over the RS-PBA in the presence of homogenous, heterogeneous and anthropomorphic phantoms. The computation performance of the RS-MC was similar to the RS-PBA algorithm. For complex disease sites like breast, head and neck, and lung cancer, the RS-MC algorithm will provide significantly more accurate treatment planning.


  • Evaluation of ceramic marker for the treatment of ocular melanoma with proton therapy

    by Jatinder Saini, Stephen R Bowen, Sara St James, Tony Wong, Charles Bloch

    BioMarc SecureTM, a fiducial marker with ceramic core (zirconium oxide) and carbon coating, was evaluated for use in the localization and alignment of ocular melanoma targets using proton pencil beam scanning (PBS). Measurements and Monte Carlo (MC) simulations were performed to estimate the dose attenuation behind the marker. Imaging tests were performed to evaluate the visibility of marker for x-ray based alignment. An anthropomorphic phantom with implanted fiducial marker was scanned to obtain two-dimensional kilo-voltage (kV) x-ray and three-dimensional computed tomographic (CT) images. For dose shadow measurements, an in-house phantom was constructed using solid water, Styrofoam and EBT3 gafchromic film. Dose attenuation behind the marker was measured at multiple depths and for three cardinal orientations: parallel, perpendicular, and transverse. The measurements were performed at the proton pencil beam gantry at the Seattle Cancer Care Alliance Proton Therapy center. A beam model for pencil beam gantry was created in the validated MC simulation toolkit GATE (GEANT4 Applications for Tomographic Emission). MC simulations were set up to mimic the measurement geometry and dose attenuation behind the marker was studied for a single layer PBS beam. Additional simulations were performed in water using the clinical relevant spread out Bragg peak (SOBP) beam. Qualitative analysis of the planar kV images showed excellent visibility of marker. Reconstruction artifacts in the form of light and dark streaks were present on the CT images. The film and MC simulations showed significant dose attenuation behind the marker that worsened when marker was placed close to the distal edge. Dose shadows of up to 45% and range loss of up to 1.1 mm were seen behind the marker. The transverse marker orientation in the clinical SOBP beam showed dose reduction of up to 61% and range pull-back of 2.4 mm. The dose attenuation was found to be a function of marker orientation and location within the SOBP. The analysis showed that small volumes behind the marker can see severe under-dosing. This effect should be taken into account during the planning of treatment. Comparing the results of this study to published results for tantalum marker, the BioMarc Secure marker was found to be inferior due to its greater dose attenuation and extended dose shadow on larger underlying volume. Furthermore, its bigger physical size may mean more discomfort to patient.


  • Open Access

    Clinical Commissioning of a Pencil Beam Scanning Treatment Planning System for Proton Therapy

    by Jatinder Saini, Ning Cao, Stephen R. Bowen, Miguel Herrera, Daniel Nicewonger, Tony Wong, Charles D. Bloch

    Purpose: In this report, we present the commissioning and validation results for a commercial proton pencil beam scanning RayStation treatment planning system. Materials and Methods: The commissioning data requirements are (1) integrated depth dose curves, (2) spot profiles, (3) absolute dose/monitor unit calibration, and (4) virtual source position. An 8-cm parallel plate chamber was used to measure the integrated depth dose curves by scanning a beam composed of a single spot in a water phantom. The spot profiles were measured at 5 different planes using a 2-dimensional scintillation detector. The absolute dose/monitor unit calibration was based on dose measurements in single-layer fields of size 10 × 10 cm2. The virtual-source position was calculated from the change in spot spacing with the distance from the isocenter. The beam model validation consisted of a comparison against commissioning data as well as a new set of verification measurements. For end-to-end testing, a series of phantom plan...